title: Lapatinib in second-line treatment for metastatic breast cancer: rapid clinical benefit and long-term response.
abstract: Lapatinib, an oral dual ErbB1/2 tyrosine kinase inhibitor, is effective in the treatment of metastatic breast cancer that has progressed after trastuzumab-based first-line chemotherapy. Moreover, lapatinib has been found to be effective in patients with metastatic brain involvement. Here we report the case of a 55-year-old woman with metastatic breast cancer and brain metastasis who achieved rapid symptom improvement and long-term disease control.
authors: Michele
authors: M
authors: De Tursi
authors: Consiglia
authors: C
authors: Carella
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology* / Q000532:radiotherapy; D005260:Female; D006801:Humans; D000077341:Lapatinib; D008875:Middle Aged; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human